Read news on PHD1/2 with our app.
Read more in the app
Insilico Medicine to present three abstracts at the 2026 Crohn’s & Colitis Congress highlighting clinical, preclinical safety, and efficacy data for ISM5411, a novel gut-restricted PHD1/2 inhibitor for inflammatory bowel disease - EurekAlert!
